US Patent

US12156914 — Pharmaceutical compositions comprising bupropion and cysteine

Formulation · Assigned to Axsome Therapeutics Inc · Expires 2043-01-20 · 17y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions and dosage forms that combine bupropion and cysteine, potentially improving bupropion stability.

USPTO Abstract

This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.

Drugs covered by this patent

Patent Metadata

Patent number: US12156914
Jurisdiction: US
Classification: Formulation
Expires: 2043-01-20
Drug substance claim: No
Drug product claim: Yes
Assignee: Axsome Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.